PTCT Stock: Price, Earnings History and SEC Filings
PTC Therapeutics, Inc. (PTCT) last traded at $59.97, down 6.97% on the latest session and down 7.4% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.61 against an analyst estimate of $0.17, a beat of 258.8%.
$59.97 -6.97%
1 month-7.43%
52-week high$90.87
52-week low$58.80
Volume2.36M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PTCT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.61 | $0.17 | +258.82% |
| Jun 2026 | Jul 30, 2026 | $0.92 | $-0.17 | +641.18% |
| Mar 2026 | May 7, 2026 | $-0.03 | $-0.45 | +93.33% |
| Dec 2025 | Feb 19, 2026 | $-1.67 | $-0.21 | -695.24% |
PTCT beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
PTCT financial history
Revenue
Net income
Free cash flow
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.7B | $683M | $702M | 39.4% | $7.78 |
| 2024 | $807M | -$363M | -$114M | -45.0% | $-4.73 |
| 2023 | $938M | -$627M | -$187M | -66.8% | $-8.37 |
| 2022 | $699M | -$559M | -$389M | -80.0% | $-7.79 |
| 2021 | $539M | -$524M | -$280M | -97.3% | $-7.43 |
| 2020 | $381M | -$438M | -$212M | -115.1% | $-6.64 |
| 2019 | $307M | -$252M | -$112M | -82.0% | $-4.27 |
| 2018 | $265M | -$128M | -$35M | -48.4% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PTCT
SEC filing data is not available right now. You can search for PTCT on SEC EDGAR.
PTCT news
- PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To LossOct 31, 2026 · finance.yahoo.com
- PTC Therapeutics (PTCT) Lifts Guidance As Fair Value Stays In FocusOct 30, 2026 · finance.yahoo.com
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Oct 30, 2026 · finance.yahoo.com
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 30, 2026 · finance.yahoo.com
- PTC Therapeutics (PTCT) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- PTC Therapeutics boosts 2026 outlook on Sephience surgeOct 30, 2026 · theglobeandmail.com
- Which Gives You More High-Margin Software Growth, PTC Or Fair Isaac?Oct 30, 2026 · trefis.com
- PTC Therapeutics, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) is a US-listed public company on Nasdaq.